Compare ETD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETD | DCTH |
|---|---|---|
| Founded | 1932 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 578.4M |
| IPO Year | 1996 | 2015 |
| Metric | ETD | DCTH |
|---|---|---|
| Price | $21.90 | $15.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $27.00 | $22.00 |
| AVG Volume (30 Days) | ★ 639.2K | 367.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.15% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ 1.56 | 0.04 |
| Revenue | ★ $766,784,000.00 | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | $2.73 | $33.15 |
| P/E Ratio | ★ $14.06 | $397.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.28 | $8.12 |
| 52 Week High | $30.11 | $17.42 |
| Indicator | ETD | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 51.15 |
| Support Level | $21.10 | $9.98 |
| Resistance Level | $22.79 | $17.42 |
| Average True Range (ATR) | 0.61 | 0.39 |
| MACD | -0.22 | -0.24 |
| Stochastic Oscillator | 20.00 | 15.75 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.